$CME QuantLogix Newsdesk · 08/02/2026, 12:31 PM UTC

SEC Orders Review of Nasdaq Bitcoin Options Approval After CME (CME) Challenge

What happened

The U.S. Securities and Exchange Commission has agreed to review its earlier approval of Nasdaq-listed bitcoin options following a formal challenge filed by CME Group. CME contested the approval, prompting the regulatory body to open a review process. The outcome could affect competitive dynamics in the listed bitcoin derivatives market, where CME already operates a dominant futures franchise. No timeline for the review's conclusion has been announced.

The QL Read

CME's composite signal sits at 52/100 (Neutral) with shares barely moved at +0.24% on the day — consistent with a wait-and-see posture. In a market where 56.4% of issues are declining, a regulatory win here could sharpen the engine's neutral read, but the outcome depends entirely on the SEC's timeline.

Source: CoinDesk — "SEC to review Nasdaq bitcoin options approval after CME challenge" — 2026-08-01T15:48:27.000Z

Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.